Population Pharmacokinetics (PPK) of Plazomicin and Use of Therapeutic Drug Management (TDM) in Critically Ill Patients

Scott A. Van Wart, M.S., Ph.D.1, Julie D. Seroogy, B.S.2, Michael Trang, Pharm.D.1, Lynn E. Connolly, MD, PhD2, Christopher M. Rubino, Pharm.D.1, Adrian M. Jubb, MBChB, Ph.D., FRCPath2, Sujata Bhavnani, Pharm.D., M.S.1, Valerie Riddle, M.D., FACP3, Tomoyuki Mizuno, Ph.D.4, Alexander A. Vinks, Pharm.D., Ph.D., FCP4 and Alan Forrest, Pharm.D.1, (1)Institute for Clinical Pharmacodynamics, Schenectady, NY, (2)Achaogen Inc., South San Francisco, CA, (3)BioPharmAdvisors LLC, Bumpass, VA, (4)Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

IDWeek 2016

Download poster as PDF